Here, we characterized the essential role of FoxO1 and FoxO3 in maintaining KSHV latency and proposed that the induction of viral lytic replication by targeting FoxOs as a clinically beneficial remedy for PEL. This evidence concerns the gene FOXO3 and primary effusion lymphoma.